Omnaris (Ciclesonide) Patent Expiration, LOE Window & CMS Spending

Omnaris (Ciclesonide) by Azurity: FDA Orange Book LOE 2028-02-01, 0 AB generics, $2.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN022004 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-02-01
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.1M
2024 Medicare Part D Spend$858K
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel